Kennen MacKay
Stock Analyst at RBC Capital
(0.89)
# 3,504
Out of 4,670 analysts
39
Total ratings
47.06%
Success rate
-15.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kennen MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $4 → $5 | $2.80 | +78.57% | 1 | Apr 17, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $40 → $42 | $55.68 | -24.57% | 3 | Jun 27, 2023 | |
| AMGN Amgen | Maintains: Sector Perform | $224 → $236 | $294.53 | -19.87% | 4 | Aug 5, 2022 | |
| EXEL Exelixis | Maintains: Outperform | $32 → $31 | $35.61 | -12.95% | 2 | Nov 3, 2021 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $33 → $34 | $1.99 | +1,608.54% | 2 | Nov 3, 2021 | |
| PRTA Prothena Corporation | Maintains: Outperform | $59 → $82 | $14.60 | +461.64% | 5 | Sep 30, 2021 | |
| PBYI Puma Biotechnology | Maintains: Sector Perform | $13 → $6 | $3.00 | +100.00% | 2 | Aug 6, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $87 → $88 | $64.26 | +36.94% | 9 | Jul 29, 2021 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $42 | $22.05 | +90.48% | 1 | Apr 30, 2021 | |
| MESO Mesoblast | Initiates: Sector Perform | $48 | $10.11 | +374.78% | 1 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $175 | $5.98 | +2,826.42% | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $23 | $45.49 | -49.44% | 3 | Apr 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | n/a | $22.27 | - | 3 | Apr 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $0.85 | +1,556.80% | 1 | Sep 15, 2017 |
Nuvation Bio
Apr 17, 2024
Maintains: Outperform
Price Target: $4 → $5
Current: $2.80
Upside: +78.57%
Agios Pharmaceuticals
Jun 27, 2023
Maintains: Outperform
Price Target: $40 → $42
Current: $55.68
Upside: -24.57%
Amgen
Aug 5, 2022
Maintains: Sector Perform
Price Target: $224 → $236
Current: $294.53
Upside: -19.87%
Exelixis
Nov 3, 2021
Maintains: Outperform
Price Target: $32 → $31
Current: $35.61
Upside: -12.95%
ADC Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $33 → $34
Current: $1.99
Upside: +1,608.54%
Prothena Corporation
Sep 30, 2021
Maintains: Outperform
Price Target: $59 → $82
Current: $14.60
Upside: +461.64%
Puma Biotechnology
Aug 6, 2021
Maintains: Sector Perform
Price Target: $13 → $6
Current: $3.00
Upside: +100.00%
BioMarin Pharmaceutical
Jul 29, 2021
Maintains: Sector Perform
Price Target: $87 → $88
Current: $64.26
Upside: +36.94%
Nurix Therapeutics
Apr 30, 2021
Initiates: Outperform
Price Target: $42
Current: $22.05
Upside: +90.48%
Mesoblast
Oct 22, 2020
Initiates: Sector Perform
Price Target: $48
Current: $10.11
Upside: +374.78%
May 8, 2020
Maintains: Outperform
Price Target: $275 → $175
Current: $5.98
Upside: +2,826.42%
Apr 3, 2019
Upgrades: Outperform
Price Target: $18 → $23
Current: $45.49
Upside: -49.44%
Apr 4, 2018
Downgrades: Sector Perform
Price Target: n/a
Current: $22.27
Upside: -
Sep 15, 2017
Initiates: Outperform
Price Target: $14
Current: $0.85
Upside: +1,556.80%